Comparing the construct validity of measurement instruments for pain and stiffness in patients with axial spondyloartwhritis: cross-sectional analysis in the OASIS cohort.

Autor:	Capelusnik D; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands.; Rheumatology, Tel Aviv Sourasky Medical Center-Ichilov, Tel Aviv, Israel., Nikiphorou E; Centre for Rheumatic Diseases, King's College Hospital Charity, London, UK.; Rheumatology, King's College Hospital Charity, London, UK., Boonen A; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands.; Department of Rheumatology, Maastricht University Medical Centre+, Maastricht, Netherlands., Christensen R; Section for Biostatistics and Evidence-Based Research, Bispebjerg Hospital, Kobenhavn, Denmark.; Clinical Research, Odense University Hospital, Odense, Denmark., van der Heijde D; Rheumatology, Leiden University Medical Center, Leiden, Netherlands., Landewé R; Clinical Immunology and Rheumatology, Amsterdam University Medical Centres, Amsterdam, Netherlands.; Rheumatology, Zuyderland Medical Centre, Sittard-Geleen, Netherlands., van Tubergen A; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands.; Department of Rheumatology, Maastricht University Medical Centre+, Maastricht, Netherlands., Ramiro S; Rheumatology, Leiden University Medical Center, Leiden, Netherlands sofiaramiro@gmail.com.; Department of Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Netherlands.
Jazyk:	angličtina
Zdroj:	RMD open [RMD Open] 2024 Dec 10; Vol. 10 (4). Date of Electronic Publication: 2024 Dec 10.
DOI:	10.1136/rmdopen-2024-004775
Abstrakt:	Objectives: To compare the construct validity, including discrimination between known groups, of three pain and three morning stiffness (MS) measurement instruments. Methods: Patients with radiographic axial spondyloarthritis with 8-year data from the Outcome in Ankylosing Spondylitis International Study cohort were assessed cross-sectionally. Three instruments for pain and three for MS, all self-reported and scored 0-10, were compared. Construct validity was evaluated by testing (1) hypothesis of correlations' strength and (2) discrimination between known groups using standardised mean differences (SMD) across external constructs. Influence of contextual factors (CFs) on SMDs was investigated. Results: Of 85 patients, mean age was 54 (SD 11), mean symptom duration 31 (11) years, 71% males. All six instruments showed a good construct validity by fulfilling >75% of the hypotheses for the strength of correlation. Neck/back/hip pain (Bath Ankylosing Spondylitis Disease Activity Index-Question 2, BASDAI-Q2) and total back pain had higher SMDs compared with back pain at night across all between-group comparisons, with BASDAI-Q2 performing mostly slightly better (eg, SMD for external construct Axial Spondyloarthritis Disease Activity Score (ASDAS; ≥2.1 vs <2.1): 1.87 (BASDAI-Q2) vs 1.56 (total back pain) vs 1.07 (back pain at night)). MS-severity and severity/duration had higher SMDs across all external constructs (with MS-severity slightly better), while MS-duration performed worse (eg, SMD external construct ASDAS: 1.51 (MS-severity) and 1.39 (MS-severity/duration) vs 1.16 (MS-duration)). Influence of CFs on known group discrimination was limited. Conclusions: The recommended Assessment of SpondyloArthritis international Society Core Outcome Set (ASAS-COS) pain measurement instrument total back pain BASDAI-Q2 has the best known group discrimination. For MS, the ASAS-COS stiffness measure (MS-severity/duration) performs well although MS-severity even slightly better. Known group discrimination is overall stable across CFs. Competing Interests: Competing interests: EN received research grants from AbbVie, Alfasigma, Fresenius, Pfizer, and UCB, and honoraria or consultancy/speaker fees from AbbVie, Eli Lilly, Alfasigma, Pfizer and UCB. AB received research grants from AbbVie and Eli Lilly and honoraria or consultancy/speaker fees from Pfizer, AbbVie, Galapagos, UCB and Novartis. DvdH received consultant fees from AbbVie, Argenx, BMS, Galapagos, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB Pharma. RL received consultant fees from AbbVie, BMS, Galapagos, Eli Lilly, Novartis, Janssen, Pfizer and UCB. AvT received research grants and consultant fees from Novartis and Galapagos. SR received research grants from AbbVie, Galapagos, MSD, Novartis, Pfizer, and UCB, and honoraria or consultancy/speaker fees from AbbVie, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, UCB and Sanofi. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu